<DOC>
	<DOCNO>NCT01252693</DOCNO>
	<brief_summary>The aim study assess safety efficacy monthly regimen ozarelix administer subcutaneously ( SC ) versus Goserelin depot administer subcutaneously men Prostate Cancer . This international , multi-center , randomize , open label 84 day study . Men least 18 year age old , histologically proven prostate cancer stage , endocrine treatment indicate eligible study entry .</brief_summary>
	<brief_title>International , Multi-Center , Open Label , Randomized Study Assessing Safety Efficacy Monthly Dosing Regimen Ozarelix Versus Goserelin Depot Men With Prostate Cancer</brief_title>
	<detailed_description>Prospective study subject undergo screen procedure . Approximately 214 eligible patient enter study . Patients randomize 1:1 ratio one two treatment arm ( Ozarelix Goserelin ) . Eligible patient randomized ozarelix group receive two SC injection ozarelix 65 mg abdomen Day 1 ( leave lower quadrant , LLQ right low quadrant , RLQ ) , follow SC injection 65 mg Ozarelix ( abdomen LLQ ) day 8 receive 2 additional SC injection Ozarelix day 28 56 ( alternate injection site ) . Eligible patient randomize Goserelin receive one 3.6 mg SC injection abdomen ( LLQ RLQ ) , follow 3.6 mg SC injection Days 28 56 ( alternate injection site ) . Ozarelix reconstitute administer 65 mg injection . Patients receive two Ozarelix 65 mg subcutaneous injection ( SC ) Day 1 , one 65 mg SC injection day 8 , follow one 65 mg injection day 28 56 . The patient receive one Goserelin 3.6 mg SC injection baseline , Day 28 Day 56 .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>Patients , age 18 year old , histologically proven prostate cancer stage , endocrine treatment indicate . Screening testosterone &gt; 1.5 ng/ml Life expectancy least 12 month ECOG score ≤ 2 Patient review sign Informed consent form Patient understand willing comply protocol Any hormone therapy prior study entrance Any patient risk urinary tract obstruction spinal cord compression due potential testosterone surge History severe uncontrolled asthma , anaphylactic reaction , severe urticaria and/or angioedema History hypersensitivity towards component study drug History presence malignancy treat squamous cell /basal cell carcinoma skin within last five year ECG screen show QTc &gt; 450 m , family history long QT syndrome Abnormal laboratory result judgment investigator would affect patient 's health outcome trial • Has clinically significant medical condition ( prostate cancer ) include limited : renal , hematological , gastrointestinal , endocrine , cardiac , neurological psychiatric disease , alcohol drug abuse condition may affect patient 's health outcome trial judge investigator Taking Class IA Class III antiarrhythmic medication Has intellectual incapacity language barrier preclude adequate understanding cooperation Has receive investigational drug within last 28 day Screening visit longer consider possibly influence outcome trial Has previously participate Ozarelix trial Is part ongoing trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>